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Abstract
Background: Older adults have the highest drug utilization due to multimorbidity. Although the number of people
over age 70 is expected to double within the next decades, population-based data on their medication patterns are
scarce especially in combination with polypharmacy and potentially inappropriate medication (PIM). Our objective
was to analyse the frequency of polypharmacy, pattern of prescription (PD) and over-the-counter (OTC) drug usage,
and PIMs according to age and gender in a population-based cohort of very old adults in Germany.
Methods: Cross-sectional baseline data of the Berlin Initiative Study, a prospective cohort study of community-
dwelling adults aged ≥70 years with a standardized interview including demographics, lifestyle variables, co-
morbidities, and medication assessment were analysed. Medication data were coded using the Anatomical
Therapeutic Chemical (ATC) classification. Age- and sex-standardized descriptive analysis of polypharmacy (≥5
drugs, PD and OTC vs. PD only and regular and on demand drugs vs regular only), medication frequency and
distribution, including PIMs, was performed by age (</≥80) and gender.
Results: Of 2069 participants with an average age of 79.5 years, 97% (95%CI [96%;98%]) took at least one drug and
on average 6.2 drugs (SD = 3.5) with about 40 to 66% fulfilling the criteria of polypharmacy depending on the
definition. Regarding drug type more female participants took a combination of PD and OTC (male: 68%, 95%CI
[65%;72%]); female: 78%, 95%CI [76%;80%]). Most frequently used were drugs for cardiovascular diseases (85%,
95%CI [83%;86%]). Medication frequency increased among participants aged ≥80 years, especially for cardiovascular
drugs, antithrombotics, psychoanaleptics and dietary supplements. Among the top ten prescription drugs were
mainly cardiovascular drugs including lipid-lowering agents (simvastatin), beta-blockers (metoprolol, bisoprolol) and
ACE inhibitors (ramipril). The most common OTC drug was acetylsalicylic acid (35%; 95%CI [33%;37%])). Dose-
independent PIM were identified for 15% of the participants.
Conclusions: Polypharmacy was excessive in older adults, with not only PD but also OTC drugs contributing to the
high point prevalence. The medication patterns reflected the treatment of chronic diseases in this age group. There
was even an increase in medication frequency between below and above 80 years especially for drugs of
cardiovascular diseases, antithrombotic medication, psychoanaleptics, and dietary supplements.
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Background
Older adults often suffer from multiple morbidities
whose treatment is associated with a complexity that
often leads to polypharmacy [1]. The most commonly
used definition of polypharmacy is the concomitant use
of five or more drugs [2]. Even if this definition is ap-
plied, the reported prevalence of polypharmacy vary
widely between 27% and 84% depending on age, morbid-
ity, country, population group (primary care vs. hospital-
ized) and year of data collection [3, 4]. For population-
based studies, prevalence of polypharmacy ranged from
40 to 67% [3, 5, 6]. Polypharmacy is associated with in-
creased risks for adverse drug reactions leading to ad-
verse events such as falls, hospital admissions, and
mortality [7–12]. Such events are not only harmful to in-
dividuals but also increase healthcare costs considerably
[13, 14]. Another aspect concerning the definition of
polypharmacy is the inclusion of prescription drugs (PD)
only or all medication including over-the-counter (OTC)
drugs. This is often related to data availability and defin-
ing polypharmacy is often limited to prescription drugs
[15, 16]. But in addition to prescription drugs, OTC
drugs also contribute to the risks that are associated
with polypharmacy [17]. Also related to polypharmacy
are potentially inappropriate medications (PIM), where
the risks of a drug are outweighed by its clinical benefit
[18]. The overall PIM prevalence for community-
dwelling older adults is found to be about 20% [19].
With polypharmacy, the risk for taking PIMs is increas-
ing [20, 21].
Most of the medication is taken by older adults despite
the fact that only about one-fifth of the European Union
population is aged 65 and older [22]. Considering the
demographic shift, the number of people above the age
of 70 is predicted to double within the next decades and
the proportion of the population 80 years and older is
expected to be further increasing from 5% in 2010 to
15% in 2050 [23]. Furthermore, data from Italy showed
that polypharmacy has increased from 43 to 53% over a
period of 10 years [5]. Therefore, the burden of disease
of this age group becomes even more important for the
health systems [24]. Although this increasing fraction of
older individuals consumes most of the medication and
therefore exhibits the highest frequency of polyphar-
macy, little is known about the medication patterns of
older adults when considering both prescription and
OTC drugs. This includes the number and the type of
drugs (prescription or OTC drugs) including PIMs. The
German national surveys (GNHIES98, DEGS1) excluded
individuals older than 79 years due to feasibility reasons
[25, 26] and thus do not reflect the full range of the age-
related changes due to the demographic shift. Further-
more, most other studies investigating medication
patterns in Germany used dispensation data primarily
from statutory health insurance companies’ providers
[20, 27]. Thus, information on the presumably large part
of OTC drugs cannot be derived from these data.
The aim of this study was to analyse if the frequency
of polypharmacy, patterns of prescription and OTC drug
usage, and PIMs differed according to age and gender in




The BIS is a prospective longitudinal population-based
cohort study. Concept and design of the BIS are de-
scribed in detail elsewhere [28, 29]. In brief, the BIS
baseline visit was conducted from November 2009 until
July 2011 and 2069 participants living in Berlin and sur-
roundings were enrolled. Inclusion criteria were AOK
membership [“Allgemeine Ortskrankenkasse” (AOK)-
Nordost - Berlin’s largest statutory health insurance
fund] and an age ≥ 70 years. We chose to cooperate with
the AOK as this is one of the health insurance funds
within Germany that covers the largest number of indi-
viduals above the age of 70 years. Dialysis patients and
kidney transplant recipients, as well as nursing home
residents, were excluded at baseline. An oversampling of
very old age groups was carried out on purpose to be
able to provide reliable numbers also for these age
ranges [29]. Participants who were, for physical reasons,
not able to come to a study site were visited at home.
The study visit included a standardized computer-based
questionnaire asking about demographics, lifestyle vari-
ables, co-morbidities, and medication as well as the
assessment of anthropometric data (height, weight).
Measurements were carried out according to pre-
specified standardized operating procedures. Blood and
urine samples were taken for instant analysis. Prior to
the study, written informed consent was obtained from
all participants. The study was approved by the local
ethics committee, Charité, Berlin, Germany (EA2/009/
08). ICD-10 (tenth Revision of the International
Statistical Classification of Diseases and Related Health
Problems) coded insurance claims data complemented
these data.
Medication assessment
Medication data were collected by self-report and coded
using the Anatomical Therapeutic Chemical (ATC) clas-
sification system [30]. Participants were asked before-
hand to bring all their medications (packages/blisters) as
well as medication lists to the study visit, where a medic-
ally trained staff member conducted the medication
assessment. All current regular and on-demand prescrip-
tion and OTC medications were recorded, based on
medication plans, medication packages, and patient self-
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reports, and entered into the standardized computer-
based questionnaire. The questionnaire was linked to a
drug database which automatically assigned relevant
drug information including prescription requirement
and the ATC code on entry. This could be provided for
86.3% of all drugs and for 100% of the prescription
drugs. All others, mainly vitamins, minerals, and dietary
supplements were coded manually. Medication was clas-
sified as either prescription drugs or OTC drugs. OTC
drugs were defined as herbal medicines, dietary supple-
ments, or nonprescription drugs according to the medi-
cinal products act [31]. Medication frequencies at the
ATC level are only shown for point prevalences higher
than 5% unless it is a top 10 listing. We categorized the
number of drugs utilized into groups of 0, 1–4, 5–9
and ≥ 10. Polypharmacy was defined as (1) taking 5 or
more regular and on demand PD and OTC drugs, (2) 5
or more regular and on demand PD or (3) 5 and more
regular PD.
Definition and identification of PIMs
Potentially inappropriate medications for older adults
(PIMs) were identified by application of the Germany-
specific PRISCUS list [32]. The list was compiled
through preliminary qualitative analyses of international
PIM lists, systematic literature search and a panel of ex-
perts through a Delphi process. As exact dosing was not
available in our dataset, we identified dose-independent
PIMs based on the ATC code.
Variables
The standardized face to face interview included (1)
sociodemographic factors, (2) socioeconomic status (in-
come and education; CASMIN [33]) (3) risk factors such
as blood pressure (mean of two measurements), body
mass index (BMI, </≥30), smoking (ever, never), alcohol
intake (≥3 times per week, ≤2 times per week to 1 time
per month, < 1 time per month), diabetes mellitus (in-
take of antidiabetic medication or haemoglobin A1c
[HbA1c]-level of > 6.5%, yes/no), arterial hypertension
(intake of antihypertensive medication, yes/no), myocar-
dial infarction, stroke, and cancer (all self-reported, yes/
no). The age-adjusted Charlson Comorbidity Index
(CCI) [34, 35] was assessed by reviewing the AOK claims
data. Glomerular filtration rate (GFR) was calculated by
the BIS2 equation [36] based on serum creatinine and
cystatin C and analysed in two categories (</≥60ml/
min/1.73m2).
Statistical Analysis
The aim of the analysis was to investigate the medication
frequency and distribution among a population of older
adults below and above 80 years. To account for the
oversampling of older age groups (≥90 years) which had
been applied during enrolment, we weighted our data
according to the age and sex distribution of the source
population (AOK-Nordost section Berlin and surround-
ings). According to the available population data from
the AOK, weighting by sex and age was performed indi-
vidually in 5-year increments up to the age of 89 and
cumulatively for ≥90 years. Weighted counts were only
rounded to the nearest integer for tables. Descriptive
analysis included absolute and relative frequencies,
means, standard deviations, and medians, standardized
by age and sex. Differences between the age groups were
analysed using chi-square tests for proportions. 95%-
confidence intervals (95%CI) were calculated for selected
proportions. No imputation for missing values was ap-
plied with the exception of the ATC code. Formally, the
level of significance was 0.05 (two-sided) for each ana-
lysis; no adjustment for multiple testing was done. Com-
mercially available software (IBM SPSS Statistics 25.0
and R 3.4.3) was used.
Results
Main baseline characteristics of the study cohort by the
number of drugs
Cross-sectional BIS-baseline data on medication infor-
mation for analysis were available for all 2069 partici-
pants. The age and sex distribution of the subpopulation
aged ≥70 years of the AOK-Nordost-Berlin was used for
weighting all analyses. Table 1 displays baseline charac-
teristics by the number of drugs. Of all study partici-
pants aged 70 to 99 years, 97% (95%CI [96%;98%]) took
at least one drug; on average 6.2 drugs (SD = 3.5; me-
dian = 6.0, IQR [4.0;8.0]) were taken. Mean age was 79.5
years, and more females (63%) were participating. Ap-
proximately half of the participants described their gen-
eral state of health as “good”. The unstandardized main
characteristics of the study population by the number of
drugs are displayed in Additional file 1: Table S1.
Considering the number of drugs, 31% (95%CI [29%;
33%]) took 1–4 drugs, 50% (95%CI [48%;53%]) 5–9, and
16% (95%CI [14%;18%]) ten or more drugs. With a rising
number of drugs we observed an increase in age, and
participants reporting higher numbers of drugs exhibited
higher frequencies of morbidities such as hypertension,
diabetes, myocardial infarction, stroke, cancer, reduced
kidney function, and obesity. This also held true for the
Charlson Comorbidity Index (CCI). Differentiating be-
tween the drug categories shows that most participants
(74%, 95%CI [72%;76%]) used a combination of OTCs
and PDs. About half (53%; 95%CI [49%;57%]) of the par-
ticipants with 1–4 drugs, 86% (95%CI [83%;88%]) with
5–9 drugs and 94% (95%CI [90%;96%]) of the partici-
pants with ten or more drugs were taking a combination
of OTCs and prescription medication. One-fifth of the
participants were taking PDs only and 3% OTCs only.
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Table 1 Main baseline characteristics of the total BIS cohort by number of drugs
Number of drugs
Total 0 1–4 5–9 ≥10
n (%) 2069 (100) 60 (3) 635 (31) 1044 (50) 330 (16)
Age (mean ± SD), years 79.5 ± 6.6 76.4 ± 5.7 78.1 ± 6.3 80.2 ± 6.6 80.7 ± 6.6
Female, n (%) 1307 (63) 20 (34) 384 (60) 685 (66) 218 (66)
Education (CASMIN-short)a, n (%)
Low 1285 (62) 36 (59) 397 (63) 648 (62) 205 (62)
Middle 434 (21) 11 (18) 118 (19) 238 (23) 67 (20)
High 340 (17) 14 (23) 118 (19) 152 (15) 57 (17)
Income, € (%)
< 1000 € 639 (36) 17 (32) 200 (37) 321 (36) 101 (36)
1000–1999 € 1021 (58) 33 (61) 306 (57) 516 (58) 166 (60)
≥ 2000 € 106 (6) 4 (7) 35 (7) 56 (6) 11 (4)
Hypertensionb, n (%) 1629 (79) n.a. 396 (62) 916 (88) 317 (96)
Diabetes mellitusc, n (%) 538 (26) 2 (3) 84 (13) 299 (29) 153 (47)
Myocardial infarction, n (%) 247 (12) 0 32 (5) 135 (13) 80 (24)
Stroke, n (%) 172 (8) 1 (1) 35 (6) 94 (9) 42 (13)
Cancer, n (%) 435 (21) 8 (13) 118 (19) 218 (21) 92 (28)
eGFRBIS2
d < 60ml/min/1.73m2, n (%) 1041 (50) 10 (17) 234 (37) 573 (55) 223 (68)
CCI (mean ± SD) 6.9 ± 3.0 4.4 ± 2.1 5.6 ± 2.4 7.2 ± 2.8 9.0 ± 3.3
BMI≥ 30 kg/m2, n (%) 573 (28) 3 (5) 148 (23) 300 (29) 122 (37)
Smoking (ever), n (%) 934 (45) 36 (59) 253 (40) 486 (47) 159 (48)
Alcohol intake (%)
< 1/month 964 (47) 19 (32) 253 (40) 505 (49) 187 (57)
≥ 1/month - 2/week 712 (35) 23 (38) 249 (40) 340 (33) 100 (31)
≥3/week – daily 376 (18) 19 (31) 127 (20) 190 (18) 40 (12)
Physical activity, n (%)
< 1/week 528 (26) 10 (16) 96 (15) 287 (28) 135 (41)
1–5/week 947 (46) 16 (26) 310 (49) 484 (47) 138 (42)
> 5/week 588 (29) 35 (58) 229 (36) 268 (26) 57 (17)
Subjective general state of health, n (%)
excellent 86 (4) 11 (18) 44 (7) 27 (3) 4 (1)
good 966 (47) 42 (69) 392 (62) 443 (43) 89 (27)
moderate 796 (39) 7 (12) 176 (28) 446 (43) 166 (51)
poor 180 (9) 1 (1) 17 (3) 106 (10) 57 (17)
very poor 29 (1) 0 1 (0.2) 15 (1) 12 (4)
Drug categorye, n (%)
OTC only 62 (3) n.a. 58 (9) 4 (0.4) 0
PD only 407 (20) n.a. 241 (38) 145 (14) 21 (6)
PD and OTC combined 1539 (74) n.a. 336 (53) 895 (86) 308 (94)
PIMf, n (%) 311 (15) n.a. 36 (6) 177 (17) 98 (30)
Data are means (SD, range) or absolute numbers (%).aCASMIN (Comparative Analysis of Social Mobility in Industrial Nations) [28]; bHypertension defined as
prescription of antihypertensive medication. cDiabetes defined as either HbA1c > 6.5%, or prescription of antidiabetic medication; deGFRBIS2 = GFR estimated by
the BIS2 equation; edrug category (PD – prescription drugs; OTC – over-the-counter); fPIM: Potentially Inappropriate Medications – dose independent; n.a. not
applicable; Data are standardized
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About one out of seven participants were prescribed at
least one drug classified as a dose-independent PIM for
older people. The frequency of PIMs increased from 6%
(95%CI [4%;8%]) in participants with 1–4 drugs to 30%
(95%CI [25%;35%]) in the ones with ten or more drugs.
Medication distribution by age and gender
For the analyses by age and gender participants were
classified into the following four categories: no medica-
tion (1), OTC medication only (2), prescription medica-
tion only (3) and prescription as well as OTC drugs (4).
Age and gender-specific analyses (Fig. 1) showed little
difference in the number of participants using no medi-
cation or OTC only. The frequency of participants
taking only prescription medication decreased from 24%
(95%CI [21%;28%]) to 11% (95%CI [7%;17%]) over age
groups and increased from 67% (95%CI [63%;70%]) in
the youngest to 85% (95%CI [80%;90%]) in the oldest for
the ones who took both, prescription and OTC drugs.
23% (95%CI [20%;26%]) of males took prescription drugs
only and 68% (95%CI [65%;72%]) both prescription and
OTC drugs as compared to 18% (95%CI [16%;20%]) and
78% (95%CI [76%;80%]) in females, respectively.
Polypharmacy
The number of drugs taken stratified by age groups is
summarized in Table 2. There were nearly twice as
many participants taking five or more drugs compared
Fig. 1 Medication categories by age (a) and gender (b). Data are presented on individual participant level; OTC (over-the-counter medication), PD
(prescription medication)
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to those taking four or fewer drugs. Across all age
groups, more than half of the participants fell into the
category polypharmacy (≥5 drugs). The number of par-
ticipants with polypharmacy was steadily increasing over
the age groups from 54% (95%CI [50%;58%]) in the
youngest age group up to 76% (95%CI [70%;83%]) in the
≥90-year-olds. Applying the strict definition of polyphar-
macy (≥5 regularly taken prescription drugs) except for
the ages 70–74, more than 40% of the participants were
affected.
Top ten ATC anatomical main groups and their
subgroups
Of the top ten anatomical main groups (level of indica-
tion), drugs for the treatment of the cardiovascular sys-
tem (ATC code C) were most commonly used (85%,
95%CI [83%;86%]). Of those, agents acting on the renin-
angiotensin system (C09) were the most frequent,
followed by beta blockers (C07) (Table 3). The second
most common main group was drugs of the alimentary
tract and metabolism (A; 64%, 95%CI [62%;66%]), where
mineral supplements (A12) and drugs for acid-related
disorders (A02) were the most frequent subgroups. Med-
ications for the treatment of blood and blood-forming
organs (B) came third (49%, 95%CI [47%;51%]) with an-
tithrombotic agents (B01) as the main subgroup (details
Additional file 2: Table S2). These were followed by
medication for treatment of the nervous system (N; 38%,
95%CI [36%;40%]) and musculoskeletal system (M; 34%,
95%CI [32%;36%]) with analgesics (N02) as well as anti-
inflammatory and antirheumatic drugs (M01) as most
frequently used subgroups.
Comparing the younger (70–79 years) to the older
(≥80 years) participants, there was a significant increase
in the frequency of ATC main anatomical groups C, B,
N and V (Table 3). Most of the drugs on therapeutic
subgroup level for the treatment of the cardiovascular
system (C) were significantly more often used in the 80
plus stratum. The same held true for antithrombotic
agents (B01), analgesics (N02), psychoanaleptics (N06),
drugs for treatment of bone disease (M05) and general
nutrients (V06).
ATC code on chemical substance level
Next, we analysed the medication on the chemical sub-
stance level. The ten most common prescription drugs
included a lipid-lowering agent (simvastatin), beta-
blockers (metoprolol, bisoprolol), an agent for thyroid
hormone deficiency (levothyroxine sodium), medication
for the treatment of cardiovascular diseases (blood pres-
sure, heart insufficiency and heart failure: amlodipine,
torasemide, ramipril), a drug for diabetes treatment
(metformin) and a proton-pump inhibitor (omeprazole)
(Table 4). Among the ten most frequently consumed
OTCs were acetylsalicylic acid, minerals (magnesium,
calcium), dietary supplements, and analgesics.
Overall, the three most frequent drugs were acetylsali-
cylic acid (35%, 95%CI [33%;37%], of those 96% as
Table 2 Number of drugs taken by age groups
Age groups
Total 70–74 75–79 80–84 85–89 ≥90
n 2069 644 (31) 541 (26) 426 (21) 273 (13) 185 (9)
Number of drugs (mean ± SD) 6.2 ± 3.5 5.4 ± 3.5 6.3 ± 3.4 6.8 ± 3.5 6.7 ± 3.1 7.1 ± 3.4
Number of drugs [median (IQR)] 6 (4;8) 5 (3;7) 6 (4;8) 7 (4;9) 6 (4;8) 7 (5;9)
Number of drugs [n (%)]
0 60 (3) 33 (5) 13 (2) 11 (3) 1 (1) 3 (2)
1–4 635 (31) 264 (41) 161 (30) 98 (23) 73 (27) 40 (22)
5–9 1044 (50) 273 (42) 283 (52) 230 (54) 153 (56) 104 (56)
> =10 330 (16) 75 (12) 84 (16) 87 (21) 46 (17) 37 (20)
OTC
0 468 (23) 189 (29) 115 (21) 84 (20) 56 (20) 24 (13)
1–4 1491 (72) 433 (67) 402 (74) 312 (73) 197 (72) 147 (79)
> =5 110 (5) 22 (3) 23 (4) 30 (7) 20 (7) 15 (8)
PD
0 123 (6) 58 (9) 31 (6) 18 (4) 9 (3) 7 (4)
1–4 1022 (49) 359 (56) 263 (49) 189 (44) 131 (48) 80 (43)
> =5 924 (45) 227 (35) 247 (46) 218 (51) 133 (49) 98 (53)
Polypharmacy only regular PDs 829 (40) 204 (32) 223 (41) 198 (47) 122 (45) 81 (44)
Data are standardized
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antithrombotic treatment), simvastatin (28%, 95%CI
[26%;30%]) and metoprolol (21%, 95%CI [20%;23%]).
Age-specific analyses demonstrated a significantly higher
consumption of acetylsalicylic acid and metoprolol in
participants aged ≥80 as compared to < 80 years.
Frequency of PIMs by age and gender
15% (95%CI [14%;17%]) of the participants were identi-
fied to have at least one dose-independent PIM (Table 5)
in their medication. Of the participants with PIMs, 85%
(95%CI [80%;88%]) had one PIM, 14% (95%CI [10%;
19%]) two and 1% (95%CI [0.3%;3%]) were identified
with three different PIMs. Analysis of PIMs by age and
gender demonstrated only marginal differences in the
prescription of PIMs on subgroup level. Out of 16 differ-
ent ATC subgroups found in PIMs, psychoanaleptics
(N06; 20%, 95%CI [16%;25%]), psycholeptics (N05; 19%,
95%CI [15%;24%]) and antihypertensives (C02; 14%,
Table 3 The ten most frequent (prescription drugs and over-the-counter medication) anatomical main groups (bold) and their most








ATC anatomical main group and subgroup
cardiovascular system (C) 1748 (85) 954 (80) 795 (90) < 0.001
agents acting on the renin-angiotensin system (C09) 1283 (62) 690 (58) 593 (67) < 0.001
beta blocking agents (C07) 951 (46) 514 (43) 437 (50) 0.006
lipid modifying agents (C10) 756 (37) 431 (36) 325 (37) 0.84
diuretics (C03) 569 (28) 258 (22) 311 (35) < 0.001
calcium channel blockers (C08) 525 (25) 281 (24) 243 (28) 0.050
cardiac therapy (C01) 398 (19) 155 (13) 243 (28) < 0.001
alimentary tract and metabolism (A) 1329 (64) 743 (63) 586 (66) 0.090
mineral supplements (A12) 677 (33) 360 (30) 317 (36) 0.009
drugs for acid related disorders (A02) 459 (22) 257 (22) 202 (23) 0.54
drugs used in diabetes (A10) 409 (20) 251 (21) 158 (18) 0.061
vitamins (A11) 250 (12) 129 (11) 122 (14) 0.043
blood and blood forming organs (B) 1013 (49) 507 (43) 506 (57) < 0.001
antithrombotic agents (B01) 949 (46) 470 (40) 480 (54) < 0.001
antianemic preparations (B03) 123 (6) 61 (5) 61 (7) 0.094
nervous system (N) 783 (38) 388 (33) 396 (45) < 0.001
analgesics (N02) 364 (18) 170 (14) 194 (22) < 0.001
psychoanaleptics (N06) 277 (13) 119 (10) 157 (18) < 0.001
psycholeptics (N05) 192 (9) 102 (9) 90 (10) 0.22
musculo-skeletal system (M) 704 (34) 402 (34) 302 (34) 0.89
antiinflammatory and antirheumatic products (M01) 386 (19) 237 (20) 150 (17) 0.080
antigout preparations (M04) 202 (10) 112 (10) 90 (10) 0.60
drugs for treatment of bone diseases (M05) 127 (6) 55 (5) 72 (8) 0.001
systemic hormonal preparations, excl. Sex hormones and insulins (H) 503 (24) 275 (23) 228 (26) 0.17
thyroid therapy (H03) 453 (22) 253 (21) 200 (23) 0.50
genitourinary system and sex hormones (G) 338 (16) 203 (17) 135(15) 0.28
urologicals (G04) 286 (14) 169 (14) 118 (13) 0.55
various (V) 307 (15) 152 (13) 155 (18) 0.011
general nutrients (V06) 261 (13) 126 (11) 135 (15) 0.001
respiratory system (R) 289 (14) 172 (15) 117 (13) 0.41
drugs for obstructive airway diseases (R03) 219 (11) 131 (11) 88 (10) 0.41
sensory organs (S) 154 (8) 87 (7) 67 (8) 0.85
ophthalmologicals (S01) 154 (8) 87 (7) 67 (8) 0.85
P-values shown are from age-group comparison by Chi2 test; Data are standardized
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95%CI [10%;19%]) were the three most common ones.
The ATC subgroup classes showed no significant differ-
ences between age groups and gender. Exceptions were
drugs for obstructive airway diseases (p = 0.049) which
were found almost twice as often in younger than older
participants, and psycholeptics (p = 0.039) which were
found approximately twice as often in females.
Discussion
This study used data of the BIS, a population-based co-
hort of old and very old adults [28] to give an in-depth
picture of the medication pattern in a German cohort of
people aged 70 and older. After standardization for the
age and sex distribution of the AOK-Nordost-Berlin, our
data showed that only a very small fraction of older
adults were free of any medication use, whereas the ma-
jority consumed both, prescription and OTC medication
with an average of 6.2 drugs. The number of drugs in-
creased with age. Applying the widely accepted defin-
ition of polypharmacy as intake of a minimum of five
regularly taken prescription drugs, about 40% of the par-
ticipants met this definition, but when also considering
OTC intake, this number increased to about two thirds.
The analysis by drug type (OTC only, PD only, or both)
showed that women took more often a combination of
PDs and OTCs. The most common ATC anatomical
main group was the group of drugs acting on the cardio-
vascular system. Medication frequency increased signifi-
cantly from participants aged 70–79 years to participants
80 years and older especially for drugs for the treatment
of cardiovascular diseases (e.g. beta blocker, diuretics,
ACE inhibitors), antithrombotic medication, psychoana-
leptics (e.g. antidepressants) and dietary supplements.
On chemical substance level, simvastatin was the most
commonly prescribed drug and acetylsalicylic acid the
most commonly consumed OTC. Using the German-
specific PRISCUS list, we identified dose-independent
PIMs for 15% of the participants.
Studies that display the entire medication utilization
spectrum in old age are rare. Several studies in old age
investigate polypharmacy and its implications. Other
studies focus on PIMs in old age. Many of these analyses
use health insurance claims data, which only include
information about prescribed drugs. The patient’s
Table 4 Top ten most frequently used prescription medication and OTC including herbal products and supplements on ATC









simvastatin 577 (28) 329 (28) 248 (28) 0.87
metoprolol 440 (21) 231 (20) 209 (24) 0.021
levothyroxine sodium 386 (19) 213 (18) 173 (20) 0.35
amlodipine 281 (14) 164 (14) 118 (13) 0.75
bisoprolol 274 (13) 150 (13) 124 (14) 0.35
torasemide 253 (12) 105 (9) 147 (17) < 0.001
ramipril and hydrochlorothiazid 218 (11) 130 (11) 88 (10) 0.46
ramipril 216 (10) 119 (10) 97 (11) 0.48
metformin 213 (10) 144 (12) 69 (7) 0.001
omeprazole 208 (10) 115 (10) 93 (11) 0.54
OTC including herbal products and supplements
acetylsalicylic acid 731 (35) 365 (31) 366 (42) < 0.001
magnesiuma 344 (17) 189 (16) 155 (18) 0.060
dietary supplement 226 (11) 109 (9) 116 (13) 0.004
calcium 160 (8) 85 (7) 75 (9) 0.068
ibuprofen 145 (7) 95 (8) 50 (6) 0.039
Ginkgo biloba 136 (7) 51 (4) 84 (10) < 0.001
omega-3-triglycerides incl. other esters and acids 65 (3) 38 (3) 27 (3) 0.85
tocopherol (vit E) 52 (3) 31 (3) 20 (2) 0.61
paracetamol 52 (3) 27 (2) 25 (3) 0.43
Hawthorn flower 50 (2) 14 (1) 36 (4) < 0.001
P-values shown are from age-group comparison by Chi2 test; Data are standardized
amagnesium (ATC: A12CC w/o A12CC30 and A12CC50)
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adherence to prescribed medications is critical to what is
consumed [37]. Therefore, prescribed medications do
not necessarily reflect the drugs taken regularly. In the
BIS, using the approach of self-reported medication, we
expect that we do not only record the prescribed medi-
cations but the medications actually taken. Again, other
studies focus on OTC medication or herbal and dietary
supplements. Studies such as the BIS that combine data
on both drug categories with detailed phenotyping in
old age are scarce and are conducted in younger popula-
tions (median age 49 years) or different health-care
systems (England and Wales, Brazil) [38–40]. Thus com-
parison of results is difficult due to other classifications
of prescription drugs and other medication patterns
among adults below the age of 70 years. However, when
comparing our results of the septuagenarians to the old-
est age stratum (70–79 years) of the surveys of the Ger-
man federal health reporting system (DEGS, GNHIES98)
the high medication frequency lies within a very similar
range [25, 26]. However, all other information concern-
ing the medication spectrum is presented for the entire
adult age range (18–79 years) there, so that further com-
parisons are not possible.
As multimorbidity increases in old age older adults
fulfil the criteria of polypharmacy. Prevalence estimates
of polypharmacy vary, often due to differing definitions
of the number of medications that constitute polyphar-
macy, and diverging time periods of assessment [41].
Interestingly, general practitioners usually underrate the
number of prescribed and OTC drugs especially for mul-
tiple medication users [42]. We applied different defini-
tions of polypharmacy defined as a minimum of five
drugs: regular and on demand PD and OTC, both sepa-
rated and the most narrow definition including only
regular PD. Independent of the prescription or OTC sta-
tus, the elderly are at higher risk for adverse drug reac-
tions [43]. Polypharmacy itself has been associated with
adverse events (mortality, falls, and drug reactions), hos-
pital admissions, increased length of stay and readmis-
sion to a hospital soon after discharge [7, 9, 16, 44].
However, not only the number of drugs varies between
the definitions for polypharmacy but also the type of
drugs included (prescription drugs only vs. all drugs).
We decided to include all medications since it has been
shown that about one-fifth of the OTC users were iden-
tified with at least one drug-related problem [17], and








PIMs total 311 (15) 173 (15) 139 (16) 0.47
PIM: ATC subgroup (n = 311)
psychoanaleptics (N06) 63 (20) 37 (22) 26 (19) 0.54
psycholeptics (N05) 59 (19) 30 (17) 30 (21) 0.35
antihypertensives (C02) 44 (14) 22 (13) 22 (16) 0.42
calcium channel blockers (C08) 34 (11) 16 (9) 18 (13) 0.30
drugs for obstructive airway diseases (R03) 33 (10) 23 (13) 9 (7) 0.049
urologicals (G04) 30 (10) 16 (9) 14 (10) 0.81
antiinflammatory and antirheumatic products (M01) 24 (8) 14 (8) 10 (7) 0.77








PIMs total 311 (15) 104 (14) 208 (16) 0.17
PIM: ATC subgroup (n = 311)
psychoanaleptics (N06) 63 (20) 19 (18) 44 (21) 0.55
psycholeptics (N05) 59 (19) 13 (12) 46 (22) 0.039
antihypertensives (C02) 44 (14) 20 (20) 24 (11) 0.061
calcium channel blockers (C08) 34 (11) 12 (12) 21 (10) 0.69
drugs for obstructive airway diseases (R03) 33 (10) 11 (10) 22 (11) 1.0
urologicals (G04) 30 (10) 9 (9) 20 (10) 0.79
antiinflammatory and antirheumatic products (M01) 24 (8) 9 (9) 15 (7) 0.65
cardiac therapy (C01) 20 (7) 7 (7) 13 (6) 0.85
P-values shown are from age-group comparison by Chi2 test; Data are standardized
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that at least half of the major drug-drug interactions in-
volve OTC drugs [45]. Our data demonstrate that the
number of OTCs taken by the elderly is even further in-
creasing with age. There is a difference of 26% between
the prevalence of polypharmacy only including five or
more regular drugs and including five or more regular
and on demand PD and OTC drugs. Thus, combining
prescription and nonprescription medication as well as
intermittently used drugs is important to show the full
burden of polypharmacy.
The most commonly used drugs belong to the ATC
main group of cardiovascular drugs. This is in accord-
ance with other studies [38, 40, 46] and mirrors the
treatment against the primary reason for death from
chronic cardiovascular diseases [47]. Besides drugs for
the treatment of cardiovascular diseases, the most com-
monly reported drugs were antithrombotic agents, drugs
for the treatment of the alimentary tract and metabolism
including mineral supplements, drugs for acid-related
disorders, and drugs used in diabetes. Swedish studies
presented similar results in their oldest age strata [48,
49]. Despite differences in health-care systems and medi-
cation assessment, the number one drug taken by the
elderly is often acetylsalicylic acid [4, 46, 50–52]. In the
BIS 20% of the participants used acetylsalicylic acid for
primary prevention of cardiovascular events even though
the clinical benefit for acetylsalicylic acid in primary pre-
vention for older people is controversial [53–56]. In
addition, among the top 10 list of OTCs were vitamins,
minerals and dietary supplements for which, again, the
evidence for a clinical benefit is lacking whereas the cost
of these products is immense [57].
Criteria have been developed by expert panels to in-
crease the quality in prescribing practices and medica-
tion use in older adults in order to identify and avoid
PIMs for older adults [58]. The PRISCUS list was spe-
cially designed for the German pharmaceutical market
[32]. In contrast to other studies on PIMs in old age, our
data show lower PIM frequencies (15% vs. 25%). This
could be partly due to differences in data collection.
Whereas in the BIS information on medication is docu-
mented as a point prevalence, in most other studies the
PIM prevalence is analysed within claims data reporting
a one-year prevalence [20, 27, 59]. Secondly, regional dif-
ferences in PIM prevalence have shown that there is a
geographical gradient in PIM prevalence with 24/25% in
western to 17/19% in eastern Germany [60]. Thirdly, the
fact that we only assessed dose-independent PIMs may
have caused underestimation of the prevalence in the
BIS. As shown for the European region, the most fre-
quently used PIMs belonged to the group of anxiolytics,
antidepressants, and non-steroidal anti-inflammatory
drugs [19]. In the BIS, we identified in addition the PIMs
nifedipine and doxazosin in similarly frequent amounts.
This is in accordance with data from Germany during
the same period [20, 27], which have also shown that
women receive PIMs more often than men [20, 27, 59].
We could not find these gender differences in our study
maybe due to the relatively small total number of PIMs.
The strengths of our study are its population-based
approach and in contrast to most other studies its rea-
sonable sample size of 2069 old and very old adults with
an age range of 70–99 years. As the original study popu-
lation was by (oversampling) design older than the re-
spective source, we used age and sex specific weights in
order to base our analysis on an age-sex-ratio of the
source population during the same time period. Further-
more, the thorough (including medication plans and
packaging) assessment of all medication taking into ac-
count both, prescription and OTC drugs, and the de-
tailed phenotyping of the participants contributes to the
strength of the study.
Some limitations also deserve mention. Firstly, the as-
sessment of the medication was self-reported supported
by medication plans if available. We were not able to as-
sess pill counts or dosing which would have added more
detail to the burden of medication in old age. Secondly,
we were unable to verify if the participants had in fact
consumed the medication. Thirdly, the medication as-
sessment of 13.7% of the drugs could not deliver an
ATC code information automatically. In such situations,
all available medication information systems were
accessed. In case a drug could still not be identified, an
ATC code was issued on an aggregated level. This was
mainly the case for vitamins, minerals or dietary supple-
ments (A11, A12 and V06). Thus, the percentage of
non-classified drugs in terms of ATC code was reduced
although a misclassification bias cannot be completely
excluded. Fourthly, the BIS is a local cohort placed in
Berlin with participants of a large health insurance com-
pany, AOK. Despite standardizations for the age and sex
distribution of the source population statements beyond
age and sex differences, e.g. differences between urban
and rural areas are not covered with this standardization
and can thus not be ruled out.
Conclusion
About two-thirds of old and very old adults met the def-
inition of polypharmacy and thus face its associated
risks. Polypharmacy was composed of both, prescription
and over the counter drugs. Using a stricter definition of
polypharmacy (five or more regular PD) reduces the
prevalence potentially underestimating its burden.
The medication pattern reflected the treatment of
chronic diseases in this age group. The increase in medi-
cation frequency between septuagenarians and the ones
80 years and older especially for cardiovascular disease
drugs, antithrombotic medication, psychoanaleptics, and
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dietary supplements, demonstrates the importance of
subdividing the upper age group when analysing medica-
tion patterns in older adults.
Future research should capture the indications for
medication intake in order to be able to differentiate be-
tween primary or secondary prevention. This may make
it easier to identify approaches to reduce the number of
drugs especially in multimorbid older adults.
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